Dexcom Inc [DXCM] stock is trading at $69.71, up 1.60%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DXCM shares have gain 0.53% over the last week, with a monthly amount drifted -2.50%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Dexcom Inc [NASDAQ: DXCM] stock has seen the most recent analyst activity on July 26, 2024, when Robert W. Baird downgraded its rating to a Neutral and also revised its price target to $80 from $161. Previously, JP Morgan downgraded its rating to Neutral on July 26, 2024, and dropped its price target to $75. On May 30, 2024, Redburn Atlantic initiated with a Neutral rating and assigned a price target of $130 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $165 on March 12, 2024. Raymond James upgraded its rating to Strong Buy for this stock on April 17, 2023, and upped its price target to $138. In a note dated March 29, 2023, UBS initiated an Buy rating and provided a target price of $142 on this stock.
Dexcom Inc [DXCM] stock has fluctuated between $62.34 and $142.00 over the past year. Currently, Wall Street analysts expect the stock to reach $81.86 within the next 12 months. Dexcom Inc [NASDAQ: DXCM] shares were valued at $69.71 at the most recent close of the market. An investor can expect a potential return of 17.43% based on the average DXCM price forecast.
Analyzing the DXCM fundamentals
Dexcom Inc [NASDAQ:DXCM] reported sales of 3.93B for the trailing twelve months, which represents a growth of 15.26%. Gross Profit Margin for this corporation currently stands at 0.63% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.21%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.3 and Total Capital is 0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 68.45 points at the first support level, and at 67.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 71.27, and for the 2nd resistance point, it is at 72.82.
Ratios To Look Out For
For context, Dexcom Inc’s Current Ratio is 2.82. Also, the Quick Ratio is 2.48, while the Cash Ratio stands at 0.55. Considering the valuation of this stock, the price to sales ratio is 7.10, the price to book ratio is 11.47 and price to earnings (TTM) ratio is 42.96.
Transactions by insiders
Recent insider trading involved Brown Michael Jon, EVP, Chief Legal Officer, that happened on Aug 30 ’24 when 686.0 shares were sold. Officer, MICHAEL BROWN completed a deal on Aug 30 ’24 to buy 686.0 shares. Meanwhile, EVP, Chief Legal Officer Brown Michael Jon sold 652.0 shares on Jul 31 ’24.
